NCT05300763 is a NA clinical trial of senofilcon A prototype in Visual Acuity, sponsored by Johnson & Johnson Vision Care, Inc..

Who is sponsoring NCT05300763?

NCT05300763 is sponsored by Johnson & Johnson Vision Care, Inc..

What drugs are being tested in NCT05300763?

Interventions in NCT05300763: senofilcon A prototype, Dailies Total 1.

What condition does NCT05300763 study?

NCT05300763 studies Visual Acuity.

Is NCT05300763 still recruiting?

NCT05300763 is currently completed. Last updated 22 June 2023.

Are results published for NCT05300763?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-22 · How we verify

NCT05300763

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance of Senofilcon A Investigational Lens

Completed NA Results posted Last updated 22 June 2023

What this trial tests

NA trial testing senofilcon A prototype in Visual Acuity in 344 participants. Completed in 25 May 2022.

Timeline

21 March 2022

Primary endpoint
25 May 2022

25 May 2022

Quick facts

Lead sponsor	Johnson & Johnson Vision Care, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	344
Start date	21 March 2022
Primary completion	25 May 2022
Estimated completion	25 May 2022
Sites	19 locations across United States

Drugs / interventions tested

senofilcon A prototype
Dailies Total 1

Conditions studied

Visual Acuity — all drugs for Visual Acuity →

Sponsor

Johnson & Johnson Vision Care, Inc. — full company profile →

Who can join

Adults 18 to 39, any sex, with Visual Acuity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

End of Day Comfort Primary · 2-Week Follow-up

End of day comfort was assessed using an individual item "Comfort at the End of the Day". Response set: Very Satisfied, Satisfied, Neither Satisfied nor Dissatisfied, Dissatisfied, and Very Dissatisfied.

Very Satisfied

Group	Value	95% CI
Test (Senofilcon A C3)	76
Control (Delefilcon A)	46

Satisfied

Group	Value	95% CI
Test (Senofilcon A C3)	52
Control (Delefilcon A)	58

Neither Satisfied nor Dissatisfied

Group	Value	95% CI
Test (Senofilcon A C3)	16
Control (Delefilcon A)	21

Dissatisfied

Group	Value	95% CI
Test (Senofilcon A C3)	18
Control (Delefilcon A)	35

Very Dissatisfied

Group	Value	95% CI
Test (Senofilcon A C3)	8
Control (Delefilcon A)	10

Digital Device Use Secondary · 2-Week Follow-up

Lens performance in digital device use was assessed using an individual item "Reduction in the feeling of tired eyes from using a computer or other digital device". Response set: Not Applicable, Excellent, Very Good, Good, Fair, and Poor. "Not Applicable" was excluded from the analysis.

Not Applicable

Group	Value	95% CI
Test (Senofilcon A C3)	2
Control (Delefilcon A)	9

Excellent

Group	Value	95% CI
Test (Senofilcon A C3)	65
Control (Delefilcon A)	47

Very Good

Group	Value	95% CI
Test (Senofilcon A C3)	68
Control (Delefilcon A)	59

Good

Group	Value	95% CI
Test (Senofilcon A C3)	17
Control (Delefilcon A)	26

Fair

Group	Value	95% CI
Test (Senofilcon A C3)	12
Control (Delefilcon A)	23

Poor

Group	Value	95% CI
Test (Senofilcon A C3)	6
Control (Delefilcon A)	6

Comfort Throughout the Day Secondary · 2-Week Follow-up

Comfort throughout the day was measured using an individual item "I could wear these contact lenses comfortably for as long as I wanted to". Response set: Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree.

Strongly Disagree

Group	Value	95% CI
Test (Senofilcon A C3)	12
Control (Delefilcon A)	18

Disagree

Group	Value	95% CI
Test (Senofilcon A C3)	26
Control (Delefilcon A)	48

Neither Agree Nor Disagree

Group	Value	95% CI
Test (Senofilcon A C3)	16
Control (Delefilcon A)	17

Agree

Group	Value	95% CI
Test (Senofilcon A C3)	43
Control (Delefilcon A)	43

Strongly Agree

Group	Value	95% CI
Test (Senofilcon A C3)	73
Control (Delefilcon A)	44

Comfortable Vision While Night Driving Secondary · 2-Week Follow-up

Comfortable vision while night driving was assessed using an individual item "Ability to see comfortably while driving at night". Response set: Not Applicable, Excellent, Very Good, Good, Fair, and Poor. "Not Applicable" was excluded from the analysis.

Not Applicable

Group	Value	95% CI
Test (Senofilcon A C3)	2
Control (Delefilcon A)	3

Excellent

Group	Value	95% CI
Test (Senofilcon A C3)	91
Control (Delefilcon A)	65

Very Good

Group	Value	95% CI
Test (Senofilcon A C3)	47
Control (Delefilcon A)	57

Good

Group	Value	95% CI
Test (Senofilcon A C3)	25
Control (Delefilcon A)	34

Fair

Group	Value	95% CI
Test (Senofilcon A C3)	3
Control (Delefilcon A)	9

Poor

Group	Value	95% CI
Test (Senofilcon A C3)	2
Control (Delefilcon A)	2

Sponsor's own description

This study is a controlled, randomized, subject-masked, 2-arm parallel, 2-week dispensing, bilateral evaluation where the study lenses are worn for a minimum of 5 days per week and 6 hours per day.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comfort advantages demonstrated with a novel soft contact lens: A randomized clinical trial.
Buch JR, Martin P, Xu J. · · 2024 · PMID 39553617 · DOI 10.1016/j.heliyon.2024.e39995

Verify or expand the search:

Other recruiting trials for Visual Acuity

Currently open trials in the same condition.

NCT07443215 — Evaluation of Effect of Scatter on Visual Performance · NA · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT07135180 — Exploring the Eye Care Benefits of Cordyceps Cicadae Across Different Age Groups · NA · active not recruiting
NCT04632901 — A New Parameter for the Assessment of Distance Visual Capacity: the Critical Visual Acuity (CVA) · active not recruiting

Other Johnson & Johnson Vision Care, Inc. trials

Trials by the same sponsor.

NCT07443215 — Evaluation of Effect of Scatter on Visual Performance · NA · recruiting
NCT07174596 — Evaluation of Approved Contact Lenses · NA · completed
NCT07076160 — Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses · NA · completed
NCT06967129 — Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process · NA · completed
NCT06864858 — Clinical Evaluation of Two Cosmetic Contact Lenses · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05300763 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johnson & Johnson Vision Care, Inc.
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05300763.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing